/
IRD
$4.06+$0.06 (+1.50%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$330.3M
83M shares
52-week range
$0.90 – $5.81
64% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.89%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$2.93
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $589.0K | $39.9M | $19.0M | $11.0M | $14.2M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $589.0K | $39.9M | $19.0M | $11.0M | $14.2M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $2.4M | $6.6M | $15.2M | $14.4M | $17.7M | $26.9M | $30.8M |
| Operating income | −$4.2M | −$20.0M | −$22.7M | $18.2M | −$10.6M | −$62.1M | −$38.6M |
| EBITDA | −$4.8M | −$17.8M | −$56.7M | $18.2M | −$10.0M | −$57.5M | −$48.1M |
| Net income | −$6.2M | −$24.6M | −$56.7M | $17.9M | −$10.0M | −$57.5M | −$49.6M |
| Net margin | — | — | -9625.3% | 44.9% | -52.4% | -523.4% | -349.3% |
| EPS (diluted) | -0.87 | -5.28 | -3.82 | 0.87 | -0.46 | -2.15 | -0.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $16M | $-1.13 | $-1.37–$-0.21 | 12 |
| 2027 | $15M | $-0.76 | $-1.13–$-0.42 | 10 |
| 2028 | $47M | $-0.35 | $-0.55–$-0.12 | 10 |
| 2029 | $150M | $0.00 | $0.00–$0.00 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Opus Genetics, Inc. Common Stock
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
www.opusgtx.com- Employees
- 28
- IPO / List date
- Nov 6, 2020
- HQ
- DURHAM, NC
Held by traders on TradeandTell
No one on the platform currently holds IRD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 73,209 | $333.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IRD yet.
